嵌合抗原受体T细胞(chimeric antigen receptor T cell，CAR-T)是肿瘤免疫治疗的重要手段，具有较强的抗肿瘤活性，但临床毒副反应明显。CAR-T细胞可通过识别共表达靶抗原及交叉抗原的组织等机制，引起肿瘤溶解综合征(tumor lysis syndrome，TLS)和细胞因子释放综合征(cytokine release syndrome，CRS)等全身性损伤。有效监测和及时处理是防治毒副反应的关键，本文结合多个CAR-T细胞治疗肿瘤临床研究的结果与经验，对CAR-T细胞治疗肿瘤的相关毒副反应及临床对策作一阐述。

Chimeric antigen receptor T cell (CAR-T) is an important approach of tumor immunotherapy, which has strong anti-tumor activity, but has clear clinical toxic adverse reactions. Through mechanisms of recognizing tissues with co-expressed target antigens and cross antigens, CAR-T could cause systemic injuries in whole body, namely tumor lysis syndrome (TLS) and cytokine release syndrome (CRS). Effective monitoring and real-time processing are key to prevention and treatment of the toxic adverse reactions. Combining with multiple clinical research results and experiences of CAR-T cellular immunotherapy for cancer the paper reviewed CAR-T cellular immunotherapy for cancer related toxic adverse reactions and its clinical strategies

国家科技支撑项目(No.2015BAI12B12)；国家自然科学基金资助项目(No. 81171653，31428005，31570877，31570908); 常州市科技计划 (应用基础研究) 项目 (No.CJ20159021)